{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:26:59Z","timestamp":1790954819092,"version":"4.1.0"},"reference-count":48,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,7,22]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune-related adverse events (irAEs), characterized by targeted inflammation, occur in up to 60% of patients with melanoma treated with immune checkpoint inhibitors (ICIs). Evidence proved that the baseline peripheral blood profiles of patients at risk for severe irAEs development paralleled clinical autoimmunity. Interleukin (IL)-23 blockade with risankizumab is recommended for cases that are suffering from autoimmune disease, such as autoimmune colitis. However, currently, the role of IL-23 in irAEs onset and severity remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The pro-inflammatory cytokines most associated with severe irAEs onset were identified by retrospective analysis based on GSE186143 data set. To investigate the efficacy of prophylactic IL-23 blockade administration to prevent irAEs, refer to a previous study, we constructed two irAEs murine models, including dextran sulfate sodium salt (DSS)-induced colitis murine model and a combined-ICIs-induced irAEs murine model. To further explore the applicability of our findings, murine models with graft-versus-host disease were established, in which Rag2\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      Il2rg\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice were transferred with human peripheral blood mononuclear cells and received combined cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1) treatment. Human melanoma cells were xenografted into these mice concomitantly.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here we show that IL-23 was upregulated in the serum of patients suffering from irAEs after dual anti-CTLA-4 and anti-PD-1 treatment, and increased as a function of irAEs severity. Additionally, Augmented CD4\n                      <jats:sup>+<\/jats:sup>\n                      Tems may preferentially underlie irAEs onset. Treating mice with anti-mouse IL-23 antibody concomitantly with combined CTLA-4 and PD-1 immunotherapy ameliorates colitis and, in addition, preserves antitumor efficacy. Moreover, in xenografted murine models with irAEs, prophylactic blockade of human IL-23 using clinically available IL-23 inhibitor (risankizumab) ameliorated colitis, hepatitis and lung inflammation, and moreover, immunotherapeutic control of tumors was retained. Finally, we also provided a novel machine learning-based computational framework based on two blood-based features\u2014IL-23 and CD4\n                      <jats:sup>+<\/jats:sup>\n                      Tems\u2014that may have predictive potential for severe irAEs and ICIs response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study not only provides clinically feasible strategies to dissociate efficacy and toxicity in the use of combined ICIs for cancer immunotherapy, but also develops a blood-based biomarker that makes it possible to achieve a straightforward and non-invasive, detection assay for early prediction of irAEs onset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009345","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:11:17Z","timestamp":1722471077000},"page":"e009345","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4084-3358","authenticated-orcid":false,"given":"Mingyi","family":"Ju","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China"},{"name":"Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China"},{"name":"Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyuan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China"},{"name":"Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China"},{"name":"Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China"},{"name":"Liaoning Medical Diagnosis and Treatment Center, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-0869","authenticated-orcid":false,"given":"Lianghua","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China"},{"name":"Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"2025100311182100000_12.7.e009345.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020"},{"key":"2025100311182100000_12.7.e009345.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.04.002"},{"key":"2025100311182100000_12.7.e009345.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100311182100000_12.7.e009345.4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.40043","article-title":"Review: immune\u2010related adverse events with use of checkpoint inhibitors for immunotherapy of cancer","volume":"69","author":"Suarez\u2010Almazor","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025100311182100000_12.7.e009345.5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"2025100311182100000_12.7.e009345.6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-21-1240","article-title":"Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events","volume":"28","author":"Smithy","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100311182100000_12.7.e009345.7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025100311182100000_12.7.e009345.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004"},{"key":"2025100311182100000_12.7.e009345.9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature New Biol"},{"key":"2025100311182100000_12.7.e009345.10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100311182100000_12.7.e009345.11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100311182100000_12.7.e009345.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z"},{"key":"2025100311182100000_12.7.e009345.13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/ecco-jcc\/jjad168","article-title":"Maintenance risankizumab sustains induction response in patients with Crohn\u2019s disease in a randomized phase 3 trial","volume":"18","author":"Ferrante","year":"2024","journal-title":"J Crohn's Colitis"},{"key":"2025100311182100000_12.7.e009345.14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000875","article-title":"Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma","volume":"33","author":"Gargiulo","year":"2023","journal-title":"Melanoma Res"},{"key":"2025100311182100000_12.7.e009345.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795"},{"key":"2025100311182100000_12.7.e009345.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"},{"key":"2025100311182100000_12.7.e009345.17","doi-asserted-by":"crossref","first-page":"108438","DOI":"10.1016\/j.jnutbio.2020.108438","article-title":"Soy isoflavones ameliorate experimental colitis by targeting ER\u03b1\/NLRP3 inflammasome pathways","volume":"83","author":"Gao","year":"2020","journal-title":"J Nutr Biochem"},{"key":"2025100311182100000_12.7.e009345.18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205378119","article-title":"Aging-associated and CD4 T-cell\u2013dependent ectopic CXCL13 activation predisposes to anti\u2013PD-1 therapy-induced adverse events","volume":"119","author":"Tsukamoto","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025100311182100000_12.7.e009345.19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407"},{"key":"2025100311182100000_12.7.e009345.20","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337"},{"key":"2025100311182100000_12.7.e009345.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2025100311182100000_12.7.e009345.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"2025100311182100000_12.7.e009345.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating thepopulation abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"2025100311182100000_12.7.e009345.24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26476","article-title":"Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data","volume":"6","author":"Racle","year":"2017","journal-title":"Elife"},{"key":"2025100311182100000_12.7.e009345.25","doi-asserted-by":"crossref","first-page":"1902880","DOI":"10.1002\/advs.201902880","article-title":"ImmuCellAI: a unique method for comprehensive T\u2010cell subsets abundance prediction and its application in cancer immunotherapy","volume":"7","author":"Miao","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"2025100311182100000_12.7.e009345.26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"2025100311182100000_12.7.e009345.27","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100311182100000_12.7.e009345.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.001"},{"key":"2025100311182100000_12.7.e009345.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1611421113"},{"key":"2025100311182100000_12.7.e009345.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2020.07.010"},{"key":"2025100311182100000_12.7.e009345.31","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1703481","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100311182100000_12.7.e009345.32","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i33.6016"},{"key":"2025100311182100000_12.7.e009345.33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3510"},{"key":"2025100311182100000_12.7.e009345.34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4049\/jimmunol.200.Supp.178.42","article-title":"A delicate interplay between adaptive and innate immunity caused by immunotherapy triggers tumor immunity and aseptic inflammation","volume":"200","author":"Hirschhorn","year":"2018","journal-title":"J Immunol"},{"key":"2025100311182100000_12.7.e009345.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0218-4"},{"key":"2025100311182100000_12.7.e009345.36","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.immuni.2022.08.007","article-title":"Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling","volume":"55","author":"Pawlak","year":"2022","journal-title":"Immunity"},{"key":"2025100311182100000_12.7.e009345.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41798-2","article-title":"Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and isdependent on anIL23\/IFN\u03b3axis","volume":"14","author":"Lo","year":"2023","journal-title":"Nat Commun"},{"key":"2025100311182100000_12.7.e009345.38","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000780644.17239.03","article-title":"S1778 IL12\/23 blockade therapy for refractory immune checkpoint inhibitor colitis: a case series","volume":"116","author":"Thomas","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2025100311182100000_12.7.e009345.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03522.x"},{"key":"2025100311182100000_12.7.e009345.40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41590-024-01755-7","article-title":"IL-23 stabilizes an effector Treg cell program in the tumor microenvironment","volume":"25","author":"Wertheimer","year":"2024","journal-title":"Nat Immunol"},{"key":"2025100311182100000_12.7.e009345.41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2324"},{"key":"2025100311182100000_12.7.e009345.42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000281","article-title":"Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy","volume":"8","author":"Murray-Brown","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100311182100000_12.7.e009345.43","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2025100311182100000_12.7.e009345.44","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"[Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment]","volume":"105","author":"Passat","year":"2018","journal-title":"Bull Cancer"},{"key":"2025100311182100000_12.7.e009345.45","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100311182100000_12.7.e009345.46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti\u2013PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100311182100000_12.7.e009345.47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"2025100311182100000_12.7.e009345.48","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221333","article-title":"Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration","volume":"220","author":"Zhou","year":"2023","journal-title":"J Exp Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:18:33Z","timestamp":1759515513000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/jitc-2024-009345"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009345","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}